2. MAPK/ERK Pathway Neuronal Signaling Immunology/Inflammation
  3. p38 MAPK Cholinesterase (ChE) Interleukin Related
  4. BChE/p38-α MAPK-IN-1

BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation.

For research use only. We do not sell to patients.

BChE/p38-α MAPK-IN-1

BChE/p38-α MAPK-IN-1 Chemical Structure

CAS No. : 3077831-11-6

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BChE/p38-α MAPK-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All Cholinesterase (ChE) Isoform Specific Products:

View All Isoforms
AChE BChE

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation[1].

IC50 & Target[1]

p38α MAPK

191 nM (IC50)

hBCHE

772 nM (IC50)

In Vitro

BChE/p38-α MAPK-IN-1 (Compound 95) shows inhibitory potency against hBChE (IC50 = 772 nM) and p38α MAPK (IC50 = 191 nM)[1].
BChE/p38-α MAPK-IN-1 (1-5 μM, 18 h) reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) and slightly increases anti-inflammatory cytokine IL-12 in Phytohemagglutinin (PHA) (HY-N7038)-stimulated human peripheral blood mononuclear cells (PBMCs)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BChE/p38-α MAPK-IN-1 Related Antibodies

ELISA Assay[1]

Cell Line: Phytohemagglutinin (PHA) (HY-N7038)-stimulated human peripheral blood mononuclear cells (PBMCs)
Concentration: 1, 2.5, 5 μM
Incubation Time: 18 h
Result: Reduced the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) and slightly increases anti-inflammatory cytokine IL-12.
In Vivo

BChE/p38-α MAPK-IN-1 (Compound 95) (5-10 mg/kg, i.p., 60 min before acquisition trial) improves Scopolamine (HY-N0296)-induced cognitive impairment in adult male Albino Swiss (CD-1) mice[1].
BChE/p38-α MAPK-IN-1 (10 mg/kg, i.p., once daily for 10 days) alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in adult male C57BL/6J mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male Albino Swiss (CD-1) mice were subcutaneously injected with scopolamine (1 mg/kg) 30 min before the acquisition trial of passive avoidance (PA) and novel object recognition (NOR) tasks to induce cholinergic deficit-related cognitive impairment[1]
Dosage: 5, 10 mg/kg
Administration: i.p., 60 min before acquisition trial
Result: Prolonged the step-through latency of mice in the memory retention trial at a dose of 10 mg/kg.
Improved scopolamine-induced long-term contextual memory impairment.
Increased the discrimination index of mice at a dose of 10 mg/kg.
Animal Model: Adult male C57BL/6J mice were intraperitoneally injected with LPS at doses of 2.5 mg/kg (2 days), 2 mg/kg (2 days), and 1.5 mg/kg (2 days) respectively[1]
Dosage: 10 mg/kg
Administration: i.p., once daily for 10 days
Result: Reduced the escape latency of mice in morris water maze spatial learning task.
Reduced the expression levels of inflammation-related proteins (TLR4, COX-2, and NLRP3) in mouse brains.
Had no obvious effect on the expression of cPLA2 protein.
Molecular Weight

454.56

Formula

C26H32F2N4O
CAS No.
SMILES

O=C(C1=CC2=C(C=C1CC3=CC=C(F)C=C3F)C=NN2CC4CCCCC4)NCCN(C)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BChE/p38-α MAPK-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BChE/p38-α MAPK-IN-13077831-11-6p38 MAPKCholinesterase (ChE)Interleukin RelatedILhBChEp38-α MAPKAlzheimer’s disease (AD)neuroinflammationpro-inflammatory cytokinesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BChE/p38-α MAPK-IN-1
Cat. No.:
HY-175655
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.